Artificial Intelligence Could Identify Prostate Cancer Patients Likely to Relapse After Surgery, Study Reports

Artificial Intelligence Could Identify Prostate Cancer Patients Likely to Relapse After Surgery, Study Reports
A pathology test that uses artificial intelligence could be used to examine prostate cancer samples and predict which patients are likely to relapse after surgery, a study shows. The test, called Precise MD post-op, is for patients whose disease has not yet metastasized, or spread to distant regions of the body. It automates a commonly used grading system for prostate cancer prognosis, called the Gleason score, by combining morphological and biomarker data into complex algorithms. “By refining diagnoses, we can guide patients toward the best treatment option and optimize care,” senior author Carlos Cordon-Cardo, MD, PhD, chair of the Department of Pathology at the Mount Sinai Health System and professor of pathology, genetics and genomic sciences, and oncological sciences at the Icahn School of Medicine, said in a press release. The study, "Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test," was published in the journal Prostate Cancer and Prostatic Diseases. Surgery is often the selected treatment for patients with prostate cancer whose disease is still confined to the prostate gland. But despite its good prognosis, 25-30% of men will eventually see their disease return. Identifying which patients are likely to recur is of paramount importance in improving their outcomes, as these patients could be monitored more closely or receive additional therapy, such as radiation or chemotherapy. While clinical features, like PSA levels, the Gleason score — a measure of aggressiveness based on a tumor's microscopic appearance — and tumor extension are often predictive of high-risk disease, doctors still require more accurate predictors of tu
Subscribe or to access all post and page content.